I wonder if it's the slight discount that has spooked investors. Might be more of Teva's BS - Teva spokesperson Denise Bradley said Teva will seek an en banc review of the decision by CAFC. http://www.biocentury.com/dailynews/topstory/2015-06-18/generic-copaxone-launched-after-cafc-invalidates-teva-patent